127 related articles for article (PubMed ID: 8836705)
1. Absence of tolerance in duodenal ulcer patients treated for 28 days with a bedtime dose of roxatidine or ranitidine.
Savarino V; Mela GS; Zentilin P; Cutela P; Vigneri S; Termini R; Di Mario F; Ferrana M; Malesci A; Belicchi M; Celle G
Fundam Clin Pharmacol; 1996; 10(3):304-8. PubMed ID: 8836705
[TBL] [Abstract][Full Text] [Related]
2. Roxatidine versus ranitidine in the treatment of patients with duodenal ulcer: a randomized, double-masked, multicenter study.
Zuberi SJ; Khan AQ; Irshad-ul-Haque I; Hussain A; Hasnain SS; Shah S; Sadick A; Yusuf MZ; Reuter M
Clin Ther; 1996; 18(6):1207-12. PubMed ID: 9001837
[TBL] [Abstract][Full Text] [Related]
3. Once-Daily Bedtime Dose of Roxatidine and Ranitidine in Acute Duodenal Ulcer: A Combined Assessment of Acid Inhibitory Activity and Healing Rate.
Savarino V; Mela GS; Zentilin P; Mele MR; Vigneri S; Termini R; Di Mario F; Ferrana M; Malesci A; Belicchi M
Am J Ther; 1995 Dec; 2(12):949-953. PubMed ID: 11854813
[TBL] [Abstract][Full Text] [Related]
4. Roxatidine in duodenal ulcer.
Habibullah CM; Habeeb MA; Singh SP
J Postgrad Med; 1995; 41(3):64-5. PubMed ID: 10707717
[TBL] [Abstract][Full Text] [Related]
5. Roxatidine versus ranitidine in the treatment of duodenal ulcer: a randomized, double blind, controlled, multicenter study in Thailand.
Kachintorn U; Chinapak O; Vongphanich V; Kositchaiwat C; Lekhayananda S; Khow-ean U; Suttinont C; Saowaros V; Kludchareon N; Leethochawalit M
J Med Assoc Thai; 1995 Dec; 78(12):641-7. PubMed ID: 8868007
[TBL] [Abstract][Full Text] [Related]
6. Roxatidine versus ranitidine in the treatment of duodenal ulcers: a randomized double-blind controlled multicentre study in Singapore.
Fock KM; Kang JY; Ng HS; Ng TM; Gwee KA; Lim CC
J Gastroenterol Hepatol; 1995; 10(4):379-82. PubMed ID: 8527701
[TBL] [Abstract][Full Text] [Related]
7. Twenty-four-hour intragastric acidity following early evening or bedtime administration of roxatidine in duodenal ulcer patients.
Lazzaroni M; Sangaletti O; Bargiggia S; Bensi G; Canali A; Bianchi Porro G
Aliment Pharmacol Ther; 1996 Apr; 10(2):187-91. PubMed ID: 8730248
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of roxatidine acetate. Evidence from pharmacodynamic and clinical trials.
Merki HS; Bender W; Labs R
J Clin Gastroenterol; 1989; 11 Suppl 1():S20-3; discussion S24. PubMed ID: 2572621
[TBL] [Abstract][Full Text] [Related]
9. A comparison of roxatidine and ranitidine for the acute treatment of duodenal ulcer.
Walt RP; Logan RF; Hawkey CJ; Daneshmend TK; Long RG; Cooper BT; Langman MJ; Collins M; Street R
Aliment Pharmacol Ther; 1991 Jun; 5(3):301-7. PubMed ID: 1679668
[TBL] [Abstract][Full Text] [Related]
10. Assessment of intragastric acidity in man: modern aspects, reproducibility of intragastric pH-monitoring, and pharmacodynamic results obtained with H2-receptor antagonists.
Merki HS; Witzel L; Kaufmann D; Kempf M; Muessig V; Neumann J; Scheurle E; Roehmel J; Walt RP
Scand J Gastroenterol Suppl; 1988; 146():142-52. PubMed ID: 2906458
[TBL] [Abstract][Full Text] [Related]
11. Twice daily nizatidine or ranitidine is superior to once daily dosing in elevating 24 h intragastric pH in patients with duodenal ulcer disease.
Thomson AB; Mahachai V; Bailey RJ; Kirdeikis P; Zuk L; Marriage B; Simpson I; Jamali F
J Gastroenterol Hepatol; 1996 Dec; 11(12):1171-6. PubMed ID: 9034938
[TBL] [Abstract][Full Text] [Related]
12. Do anticholinergics interact with histamine H2 receptor antagonists on night intragastric acidity in active duodenal ulcer patients?
Fiorucci S; Clausi GG; Farinelli M; Santucci L; Farroni F; Pelli MA; Morelli A
Am J Gastroenterol; 1988 Dec; 83(12):1371-5. PubMed ID: 2904218
[TBL] [Abstract][Full Text] [Related]
13. Tolerance and rebound to H2-receptor antagonists: intragastric acidity in patients with duodenal ulcer.
Wilder-Smith CH; Halter F; Merki HS
Dig Dis Sci; 1991 Dec; 36(12):1685-90. PubMed ID: 1748035
[TBL] [Abstract][Full Text] [Related]
14. Continuous intragastric pH monitoring: a real progress in the assessment of antisecretory drugs.
Savarino V
Ital J Gastroenterol; 1990; 22 Suppl 2():20-3. PubMed ID: 1983412
[TBL] [Abstract][Full Text] [Related]
15. Clinical characteristics of roxatidine acetate: a review.
Dammann HG; de Looze SM; Bender W; Labs R
Scand J Gastroenterol Suppl; 1988; 146():121-34. PubMed ID: 2906456
[TBL] [Abstract][Full Text] [Related]
16. Low bedtime doses of H2-receptor antagonists for acute treatment of duodenal ulcer.
Savarino V; Mela GS; Zentilin P; Bonifacino G; Moretti M; Valle F; Celle G
Dig Dis Sci; 1989 Jul; 34(7):1043-6. PubMed ID: 2568246
[TBL] [Abstract][Full Text] [Related]
17. Twenty-four-hour intragastric pH-metry: H2-receptor antagonist restoration of nightly gastric spontaneous alkalinization in duodenal ulcer healing.
Bianco A; Cagossi M; Piraccini R; Greco AV
Riv Eur Sci Med Farmacol; 1992; 14(5):281-91. PubMed ID: 1364062
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of nocturnal acidity is important but not essential for duodenal ulcer healing.
Bianchi Porro G; Parente F; Sangaletti O
Gut; 1990 Apr; 31(4):397-400. PubMed ID: 2186980
[TBL] [Abstract][Full Text] [Related]
19. A comparison of roxatidine acetate and ranitidine in duodenal ulcer healing.
Hüttemann W
Drugs; 1988; 35 Suppl 3():90-5. PubMed ID: 2905255
[TBL] [Abstract][Full Text] [Related]
20. Single morning and nightly doses of ranitidine 300 mg: an appraisal of their antisecretory effects by continuous pH monitoring.
Savarino V; Mela GS; Zentilin P; Sumberaz A; Cutela P; Celle G
Digestion; 1991; 48(3):141-8. PubMed ID: 1916034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
